AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28337945
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy integrated with motivational interviewing (MI-CBT)
Trial: 28337945
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy alone (CBT)
Trial: 27080115
Drug: Ibuprofen/Paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen/Paracetamol
Trial: 27080115
Drug: Diclofenac K/Paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac K/Paracetamol
Trial: 27080115
Drug: Mefenamic Acid/Paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefenamic Acid/Paracetamol
Trial: 20434544
Drug: Two-dose regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-dose regimen of combined hepatitis A and B vaccine (0, 6 months, Adult formulation)
Trial: 20434544
Drug: Three-dose regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-dose regimen of combined hepatitis A and B vaccine (0, 1, 6 months, Paediatric formulation)
Trial: 20434544
Drug: Challenge dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Challenge dose of hepatitis B vaccine administered to subjects with anti-HBs antibody concentration < or =10mIU/mL
Trial: 18300356
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy with lamivudine-IFN-alpha 2b for 48 weeks
Trial: 18300356
Drug: Lamivudine monotherapy
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine monotherapy for 48 weeks
Trial: 18300356
Drug: IFN-alpha 2b
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IFN-alpha 2b monotherapy for 24 weeks
Trial: 18300356
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with sustained virological response after 24 weeks of therapy withdrawal
Trial: 16231260
Drug: Continuous fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous fluconazole (200 mg 3 times weekly)
Trial: 11249886
Drug: Aggressive strategy
RxNorm normalized name: ZO SKIN HEALTH Aggressive Anti-Aging Program KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive strategy (maximum burr/artery >0.70 with adjunctive balloon inflation < or = 1 atm)
Trial: 7988775
Drug: Polymorphisms in
RxNorm normalized name: Murine MAb to polymorphic epithelial mucin, human milk fat globule 1
DrugBank: Pemtumomab (DB18563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymorphisms in the insulin gene region in Caucasians
Trial: 7988775
Drug: Polymorphisms in
RxNorm normalized name: Murine MAb to polymorphic epithelial mucin, human milk fat globule 1
DrugBank: Pemtumomab (DB18563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymorphisms in the insulin gene region in Tanzanian blacks
Trial: 7988775
Drug: Polymorphisms in
RxNorm normalized name: Murine MAb to polymorphic epithelial mucin, human milk fat globule 1
DrugBank: Pemtumomab (DB18563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymorphisms in the insulin gene region in Japanese orientals
Trial: 31624941
Drug: Same-day dose
RxNorm normalized name: SAMe
DrugBank: Ademetionine (DB00118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same-day dose (SDD) of polyethylene glycol (PEG) starting at 7 AM on the day of colonoscopy
Trial: 31624941
Drug: Split dose
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split dose (SPD) of polyethylene glycol (PEG) - 2 L at 9 PM the day before and 2 L from 10 AM on the day of colonoscopy
Trial: 31624941
Drug: Same-day dose
RxNorm normalized name: SAMe
DrugBank: Ademetionine (DB00118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same-day dose (SDD)
Trial: 31624941
Drug: Split dose
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split dose (SPD)
Trial: 28102979
Drug: Present‐centered therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Present‐centered therapy
Trial: 19459427
Drug: Losartan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (50 mg/day) with indapamide (1.5 mg/day)
Trial: 11473038
Drug: gliclazide (40-80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gliclazide (40-80 mg twice daily for 5 weeks)
Trial: 11473038
Drug: gliclazide (acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gliclazide (acute treatment)
Trial: 11473038
Drug: gliclazide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gliclazide (5 weeks treatment)
Trial: 8066559
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (800 micrograms beclomethasone daily)
Trial: 8066559
Drug: Bronchodilators only
RxNorm normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bronchodilators only (control group)
Trial: 28804807
Drug: Corticotropin-releasing hormone
RxNorm normalized name: corticotropin-releasing hormone
DrugBank: Corticorelin (DB05394)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticotropin-releasing hormone (CRH) injection
Trial: 28804807
Drug: NaCl (placebo)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl (placebo) injection
Trial: 21283543
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy without Atorvastatin
Trial: 19255328
Drug: AZA 5-2-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZA 5-2-2 (75 mg/m(2)/d for 5 days, then 2 days no treatment, then 75 mg/m(2)/d for 2 days)
Trial: 19255328
Drug: AZA 5-2-5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZA 5-2-5 (50 mg/m(2)/d for 5 days, then 2 days no treatment, then 50 mg/m(2)/d for 5 days)
Trial: 19255328
Drug: AZA 5
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AZA 5 (75 mg/m(2)/d for 5 days)
Trial: 16109807
Drug: Irbesartan (AT1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (AT1 receptor blocker)
Trial: 15120009
Drug: Budesonide inhaled
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide inhaled from Easyhaler (Giona Easyhaler)
Trial: 15120009
Drug: Budesonide inhaled
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide inhaled from Turbuhaler (Pulmicort Turbuhaler)
Trial: 15120009
Drug: Budesonide inhaled
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide inhaled from Turbuhaler
Trial: 15120009
Drug: Budesonide inhaled
RxNorm normalized name: budesonide Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide inhaled from Easyhaler
Trial: 10943876
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral methotrexate (MTX)
Trial: 2180405
Drug: Daily auranofin
RxNorm normalized name: Auranofin
DrugBank: Auranofin (DB00995)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily auranofin (AUR)
Trial: 395523
Drug: Danazol (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danazol (400 mg daily for 2 months)
Trial: 25865966
Drug: Blond orange
RxNorm normalized name: Orange
DrugBank: Orange (DB10549)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blond orange juice (200 mL, 3 times daily for 4 weeks)
Trial: 25865966
Drug: Control beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control beverage (200 mL, 3 times daily for 4 weeks)
Trial: 24877717
Drug: Glucevia(®) (333
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucevia(®) (333 mg per capsule, 3 capsules daily for 3 weeks)
Trial: 22038507
Drug: Glutamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamine (0.5 g/kg ideal body weight/day for 2 months)
Trial: 22038507
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein (0.5 g/kg ideal body weight/day for 2 months)
Trial: 20226365
Drug: Conventional conservative
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional conservative therapy (CCT)
Trial: 16257842
Drug: Epoetin-alpha (aiming
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin-alpha (aiming for hemoglobin level 135-160 g/l)
Trial: 12153826
Drug: Risperidone (0.02-0.06
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (0.02-0.06 mg/kg per day)
Trial: 8651966
Drug: IVIg (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIg (5 mg/kg)
Trial: 7996367
Drug: Albumin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albumin (5 mg/kg)
Trial: 29669026
Drug: Modified vaccinia
RxNorm normalized name: Modified vaccinia ankara
DrugBank: Modified vaccinia ankara (DB15483)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified vaccinia Ankara (MVA)-vectored HIV-1 bivalent mosaic immunogen vaccine
Trial: 29669026
Drug: Prototype Ad26.ENVA.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prototype Ad26.ENVA.01 vaccine
Trial: 28848908
Drug: Formoterol fumarate
RxNorm normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Formoterol fumarate delivered by metered dose inhaler (MDI) at doses of 7.2, 9.6, and 19.2 micrograms
Trial: 28848908
Drug: Formoterol fumarate
RxNorm normalized name: Formoterol Fumarate
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Formoterol fumarate delivered by metered dose inhaler (MDI) at 9.6 micrograms
Trial: 16408815
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 600 mg fudosteine
Trial: 16408815
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 400 mg fudosteine
Trial: 16408815
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 200 mg fudosteine
Trial: 16408815
Drug: Multiple dose
RxNorm normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple dose of 400 mg fudosteine (3 times a day for 5 days)
Trial: 9737803
Drug: Intramuscular soluble
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular soluble insulin
Trial: 9737803
Drug: Subcutaneous soluble
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous soluble insulin
Trial: 9737803
Drug: Intramuscular insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular insulin lispro
Trial: 15336577
Drug: Subcutaneous insulin
RxNorm normalized name: subcutaneous insulin pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous insulin lispro
Trial: 2221971
Drug: Lowest plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lowest plasma prolactin concentrations (<1000 mU/l, 32.9 micrograms/l)
Trial: 350145
Drug: Karminomycin 5
RxNorm normalized name: dactinomycin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Karminomycin 5 mg/m2 daily for 5 days
Trial: 350145
Drug: Karminomycin 6
RxNorm normalized name: Dactinomycin
DrugBank: Dactinomycin (DB00970)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Karminomycin 6 mg/m2 twice a week for 2-3 weeks
Trial: 21784529
Drug: BDP‐HFA 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP‐HFA 100 μg BID
Trial: 21784529
Drug: BDP‐CFC 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP‐CFC 200 μg BID
Trial: 21784529
Drug: BDP‐HFA 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BDP‐HFA 100 μg BID and BDP‐CFC 200 μg BID
Trial: 19351812
Drug: Weekly physical
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly physical therapy
Trial: 19351812
Drug: Monthly physical
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly physical therapy
Trial: 16879975
Drug: Cycle HRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cycle HRT schedule (0.625 mg conjugated estrogen from days 1 to 28 + 5 mg medroxyprogesterone acetate from days 18 to 28) for 2 months (n=25)
Trial: 16879975
Drug: Continue HRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue HRT schedule (0.625 mg conjugated estrogen + 2.5 mg medroxyprogesterone acetate from days 1 to 28) for 2 months (n=25)
Trial: 9227252
Drug: 89Sr chloride
RxNorm normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 89Sr chloride therapy
Trial: 25044799
Drug: lorcaserin 10
RxNorm normalized name: lorcaserin 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lorcaserin 10 mg bid
Trial: 18384230
Drug: Continue neuroleptic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continue neuroleptic treatment for 12 months
Trial: 18384230
Drug: Placebo (discontinue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (discontinue treatment)
Trial: 15690237
Drug: Prednisolone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (30 mg/kg) added to the priming solution of the cardiopulmonary bypass circuit
Trial: 15690237
Drug: No steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No steroids (nonsteroid group)
Trial: 7551381
Drug: Nutritional intervention
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional intervention (420 kcal daily high caloric supplement)
Trial: 7551381
Drug: Nutritional intervention
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional intervention + Nandrolone decanoate (25 mg for women, 50 mg for men, injected intramuscularly on Days 1, 15, 29, and 43)
Trial: 30880937
Drug: Antibiotic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic treatment for COPD exacerbation
Trial: 15570142
Drug: 20 g
RxNorm normalized name: PEG-20 glyceryl oleate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 g of casein (CS)
Trial: 9135492
Drug: Epirubicin 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 60 mg/m2/24 h (total dose for cycle 180 mg/m2) days 1, 2 and 3 (group A)
Trial: 9135492
Drug: Epirubicin 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 60 mg/m2/24 h days 1, 2 and 3 and cisplatin 30 mg/m2/24 h days 2, 3, 4 and 5 (group B)
Trial: 16428570
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg lidocaine + 8 mg dexamethasone
Trial: 16428570
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg lidocaine
Trial: 16428570
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg lidocaine for IVRA and 8 mg dexamethasone IV to the nonsurgical arm
Trial: 9354316
Drug: Omeprazole 40
RxNorm normalized name: omeprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 40 mg once daily for 3 days
Trial: 9354316
Drug: Placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for 3 days
Trial: 17944274
Drug: Live, attenuated
RxNorm normalized name: Ebola Zaire vaccine (live, attenuated)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live, attenuated intranasal influenza vaccine
Trial: 17944274
Drug: Novel inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel inhibitors for influenza, RSV, and rhinovirus infections
Trial: 17944274
Drug: Antiviral therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiviral therapies and vaccine strategies
Trial: 11268947
Drug: MFL (Methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MFL (Methotrexate 100 mg/m2 and 5-FU 600 mg/m2 followed by leucovorin rescue)
Trial: 11268947
Drug: UFT-MMC (Mitomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT-MMC (Mitomycin C 12 mg/m2 intraoperatively and 6 mg/m2 every other week for 2 months, oral UFT 375 mg/m2/day for 3 years or longer)
Trial: 9917606
Drug: Cementless taper
RxNorm normalized name: caper berry extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cementless taper design femoral components
Trial: 9917606
Drug: Cemented femoral
RxNorm normalized name: Sus scrofa temporal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cemented femoral implants
Trial: 7819596
Drug: Intravenous immunoglobulins
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulins (100 mg/kg)
Trial: 7819596
Drug: Intravenous immunoglobulins
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulins (250 mg/kg)
Trial: 7819596
Drug: Intravenous immunoglobulins
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulins (400 mg/kg)
Trial: 3278367
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g apple pectin USP powder twice daily
Trial: 3278367
Drug: One tablet
RxNorm normalized name: Hydone Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One tablet matching ranitidine placebo at night
Trial: 31359829
Drug: Romiplostim administration
RxNorm normalized name: Romiplostim
DrugBank: Romiplostim (DB05332)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Romiplostim administration after transplantation
Trial: 23778995
Drug: Control (conventional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (conventional systemic therapy)
Trial: 17058828
Drug: Ginaton 1
RxNorm normalized name: Genaton
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginaton 1 mg/kg by intravenous dripping before open heart for CPB
Trial: 10720289
Drug: Cladribine 0.07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cladribine 0.07 mg/kg/day for 5 consecutive days every 4 weeks for two cycles (total dose 0.7 mg/kg)
Trial: 10720289
Drug: Cladribine 0.07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cladribine 0.07 mg/kg/day for 5 consecutive days every 4 weeks for six cycles (total dose 2.1 mg/kg)
Trial: 8645512
Drug: Omeprazole: an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole: an initial bolus of 80 mg + perfusion of 3.3 mg/h
Trial: 8645512
Drug: Omeprazole: an
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole: an initial bolus of 80 mg + 40 mg/12 h
Trial: 8645512
Drug: Omeprazole: 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole: 40 mg/8 h
Trial: 8645512
Drug: Ranitidine: perfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine: perfusion of 12.5 mg/h
Trial: 8645512
Drug: Ranitidine: 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine: 50 mg/4 h
Trial: 19684633
Drug: Total body
RxNorm normalized name: Total Body Massager Item
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total body MRI-governed involved compartment irradiation (ICI) followed by high-dose chemotherapy (HDC) and stem cell rescue (SCR)
Trial: 15925814
Drug: PEFG regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEFG regimen (40 mg/m2 cisplatin, 40 mg/m2 epirubicin, 600 mg/m2 gemcitabine, 200 mg/m2 fluorouracil)
Trial: 15925814
Drug: Gemcitabine alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine alone (1000 mg/m2)
Trial: 12689974
Drug: Interleukin-2 receptor
RxNorm normalized name: Interleukin-2 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interleukin-2 receptor antibodies
Trial: 10646047
Drug: Racecadotril (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racecadotril (100 mg three times daily)
Trial: 10646048
Drug: Loperamide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide (2 mg after each diarrhoeic stool)
Trial: 7201837
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg antipyrine (phenazone) administered intravenously (i.v.)
Trial: 7201837
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg antipyrine (phenazone) administered orally (p.o.)
Trial: 7201837
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg antipyrine (phenazone) administered i.v. in smokers
Trial: 7201837
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg antipyrine (phenazone) administered i.v. in non-smokers
Trial: 7201837
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg antipyrine (phenazone) in smokers
Trial: 30665829
Drug: telmisartan/amlodipine/rosuvastatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: telmisartan/amlodipine/rosuvastatin (80 mg/10 mg plus 20 mg)
Trial: 30665829
Drug: telmisartan/rosuvastatin (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: telmisartan/rosuvastatin (80 mg plus 20 mg)
Trial: 30665829
Drug: telmisartan/amlodipine (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: telmisartan/amlodipine (80 mg/10 mg)
Trial: 27502582
Drug: Etoricoxib 60
RxNorm normalized name: etoricoxib 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 60 mg to 90 mg escalation
Trial: 27502582
Drug: Etoricoxib 60
RxNorm normalized name: etoricoxib 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoricoxib 60 mg steady dose
Trial: 22238577
Drug: L-DOPA (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-DOPA (0, 100/25, 200/50 mg, Sinemet)